Kidney drug may work through gut bacteria, study hints

NCT ID NCT05965440

Completed Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 50 non-diabetic people with chronic kidney disease to see if the drug dapagliflozin changes the types of bacteria in their gut. Researchers measured gut bacteria diversity and related waste products in the blood before and after 12 weeks of treatment. The goal was to understand how dapagliflozin might protect the kidneys beyond its known effects on blood sugar.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin
What this could lead to: If successful, this could help explain how dapagliflozin protects the kidneys, potentially leading to better treatments for chronic kidney disease.
What could go wrong: This is a small, observational study with only 50 participants and no control group. It looks at biological changes, not direct health outcomes, so results may not lead to clear conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES

Contacts and locations

Locations

Nephrology department, Hôpital Lyon Sud, Hospices Civils de Lyon

Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.